Attana announced in preparation for CE-IVD certification an independent evaluation of the AttanaSARS-CoV-2 immunoassay will, in the coming few weeks, be performed by a leading IVD specialist research company. Upon completion, Attana will have its own diagnostic data supplemented by evaluations from both an academic institution and a commercial third-party. This combined data will form the technical basis for the various ongoing regulatory processes planned in 2021 as well as the new IVD-R requirements which will come into effect in 2022. Additionally, Attana has begun preparations for partly supplementing its ISO 9001 certification with ISO 13485 standards to facilitate the transition from a supplier of laboratory equipment to also include IVD products for clinical diagnostic use.